Damien Conover
-
Amylin Rejects $3.5 Billion Bid From Bristol; Offer Represents Premium to Firm's Stand-Alone Value
… Amylin ranked Number 18 in Morningstar's annual biotechnology takeout list as our view of the company's strong need for a partner was tempered by fairly disappointing pipeline prospects. Damien Conover , CFA contributed to this note.
-
Top 10 Dividend-Yielding Stocks of Our Ultimate Stock-Pickers
… generator, Morningstar analyst Damien Conover believes the firm is in a much ..... Lilly LLY Morningstar analyst Damien Conover believes that Eli Lilly faces ..... its peers, Morningstar analyst Damien Conover notes that Merck is investing …
-
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
… fact that Johnson & Johnson remains "an attractive business at its price," an opinion held by Morningstar analyst Damien Conover , who considers the firm to be "one of the best-positioned companies in the pharmaceutical industry." Buffett …
-
Significant Upside for Pharma Stock Prices, Dividends… update on the Big Pharma space, I am here today with Damien Conover ; he is our associate director of health care. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser : So toward …
an update on the Big Pharma space, I am here today with Damien Conover ; he is our associate director of health care. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser : So toward the end of 2011 we saw a pretty big runup in some -
Black Friday Picks for Your Investment Shopping Cart… rating, I can't number which, and it does bounce around a little bit based on the stock price. But our analyst Damien Conover does think that the company has a very attractive product pipeline. So, he thinks that there is a lot of upside …
around a little bit based on the stock price. But our analyst Damien Conover does think that the company has a very attractive product pipeline. So, he thinks that there is a lot of upside in -
Sanofi's CEO Discusses Q3 2011 Results - Earnings Call Transcript
… Berrigaud – Bryan Garnier Vincent Meunier – Exane BNP Paribas Luisa Hector – Credit Suisse Mark Beards – Goldman Sachs Damien Conover – Morningstar Presentation Operator Welcome to the 2011 Q3 Results Conference Call. Today, I am pleased to present Mr …
-
Option Spotlight: Keep Your Portfolio Healthy With These Health-Care Picks
… recently announced plans to split into two companies . Morningstar's associate director of health-care research Damien Conover , CFA, likes the idea and believes the shares are a buy right now. Splitting the firm into two should not affect …
-
Scaling Back?… will make sense. We don't think it's going to add a ton of value or increase our fair value, as I talked to Damien Conover , the analyst on Abbott earlier this week. But we think it might help the market realize some of that value and have …
ton of value or increase our fair value, as I talked to Damien Conover , the analyst on Abbott earlier this week. But we think it might help the market realize some of that value and -
Abbott Breakup Could Be CatalystSpinning off the volatile drug business could help investors realize the true value of Abbott Labs sooner, says Morningstar's Damien Conover .
-
Top 10 Dividend-Yielding Stocks of Our Ultimate Stock-Pickers
… Lilly LLY Morningstar analyst Damien Conover believes that Eli Lilly faces ..... Valtrex. Morningstar analyst Damien Conover believes Glaxo is in a much better ..... chances of approval, our analyst Damien Conover thinks Merck greatly improved …